Samsung Biologics is the world's largest biologics CDMO by capacity, and opened a dedicated ADC conjugation facility in 2025.
Samsung Biologics, based in Incheon and listed as 207940.KS, is the world's largest biologics CDMO by capacity and opened a dedicated antibody-drug conjugate conjugation facility in 2025. It runs mammalian cell culture at unprecedented scale at its Songdo Plant 5, adds ADC conjugation and fill-finish, and announced the spin-off of Samsung Bioepis in 2025. OnCo links it to ADC bioconjugation manufacturing, antibody manufacturing and sterile fill-finish. Whether Korean capacity becomes the main beneficiary as sponsors diversify ADC manufacturing away from China is the open question. The ADC manufacturing page carries the wider picture.
Shares ADC bioconjugation manufacturing (CDMOs), Antibody manufacturing (CHO bioprocessing), Sterile fill-finish and lyophilisation, GMP, inspections, Form 483s and warning letters and the tag supporting.
Shares Antibody manufacturing (CHO bioprocessing), Downstream purification (Protein A capture, viral clearance, polishing) and the tag supporting.
Shares Sterile fill-finish and lyophilisation, GMP, inspections, Form 483s and warning letters and the tag supporting.
Shares ADC bioconjugation manufacturing (CDMOs), The ADC supply chain (antibody, payload-linker, conjugation, fill) and the tag supporting.
Shares Antibody manufacturing (CHO bioprocessing), Downstream purification (Protein A capture, viral clearance, polishing) and the tag supporting.
Shares ADC bioconjugation manufacturing (CDMOs), The ADC supply chain (antibody, payload-linker, conjugation, fill) and the tag supporting.
Shares ADC bioconjugation manufacturing (CDMOs), The ADC supply chain (antibody, payload-linker, conjugation, fill) and the tag supporting.
Shares ADC bioconjugation manufacturing (CDMOs), The ADC supply chain (antibody, payload-linker, conjugation, fill) and the tag supporting.